Form 4: Sage Therapeutics Director George Golumbeski Granted 21,500 Stock Options

Sage Therapeutics, Inc. Director George Golumbeski was granted 21,500 stock options with an exercise price of $6.77, vesting over approximately one year.

Summary

• George Golumbeski, a Director of Sage Therapeutics, Inc. (SAGE), was granted 21,500 stock options.
• The transaction date for this grant was June 11, 2025.
• The exercise price for these stock options is $6.77 per share.
• The options were issued under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan, specifically as part of the Non-Employee Director Compensation Program.
• These options will vest in full upon the earlier of June 11, 2026, or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, contingent on continued service as a director.
• The stock options have an expiration date of June 11, 2035.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine disclosure of director compensation via stock options, which is a standard practice and does not inherently indicate significant positive or negative company performance or outlook.

Positives

• The grant of stock options to Director George Golumbeski aligns his interests with those of shareholders, incentivizing long-term company performance.

Negatives

• The issuance of new stock options could lead to minor future dilution for existing shareholders if exercised, although this is a standard component of director compensation.

Risks

• The value of the stock options is subject to the future performance of Sage Therapeutics' common stock; if the stock price does not exceed the exercise price of $6.77, the options may not be profitable.

Future Outlook

The document indicates a future vesting event for the granted stock options, contingent on continued service as a director until June 11, 2026, or the day prior to the 2026 Annual Meeting of Stockholders.

Industry Context

This Form 4 filing is a routine disclosure of insider compensation, common across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors like Sage Therapeutics, where equity-based compensation is a standard practice for attracting and retaining talent and aligning interests.

Comparison to Industry Standards

• NA

Corporate Governance

Related Party Transactions

• The grant of 21,500 stock options to George Golumbeski, a Director of Sage Therapeutics, Inc., constitutes a related party transaction as it is compensation provided to a member of the company's board.

Stakeholder Impact

• Shareholders: Potential for minor future dilution if options are exercised, but also benefit from aligned director incentives.
• Director (George Golumbeski): Receives equity-based compensation, aligning personal financial interests with the company's long-term stock performance.

Next Steps

• The stock options will vest upon the earlier of June 11, 2026, or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service.

Key Dates

Keywords

Sage Therapeutics, SAGE, Stock Option Grant, SEC Form 4, Insider Transaction, Director Compensation, Equity Incentive Plan, George Golumbeski